IR
$79.42
+0.48
(+0.61%)
As of Oct 20, 2026, 11:03 AM EDT
Price history
Disc Medicine Inc (IRON) is trading up at $79.42 (+0.61%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Disc Medicine Inc net income history (FY2020–FY2025)
Net income
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$34.0M | −$30.9M | −$47.5M | −$91.1M | −$129.7M | −$236.0M |
| Net income | −$40.8M | −$36.0M | −$46.8M | −$76.4M | −$109.4M | −$212.2M |
| EPS (diluted) | −$4320.00 | −$1638.00 | −$45.05 | −$3.42 | −$3.96 | −$6.01 |
| Balance sheet | ||||||
| Cash and equivalents | $4.50M | $88.0M | $194.6M | $360.4M | $192.4M | $91.1M |
| Total assets | $8.32M | $92.4M | $200.2M | $368.0M | $496.8M | $806.9M |
| Total liabilities | $30.2M | $14.8M | $23.6M | $22.9M | $53.2M | $67.1M |
| Long-term debt | $14.0M | — | — | $0 | $28.3M | $29.2M |
| Shareholders' equity | −$28.8M | −$64.2M | $176.6M | $345.1M | $443.6M | $739.8M |
| Cash flow | ||||||
| Operating cash flow | −$32.7M | −$27.5M | −$42.3M | −$73.5M | −$93.9M | −$180.4M |
| Capital expenditure | $22.0K | $68.0K | $151.0K | $89.0K | $505.0K | $933.0K |
| Free cash flow | −$32.7M | −$27.6M | −$42.4M | −$73.6M | −$94.4M | −$181.3M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$32.9M | −$34.5M | −$39.9M | −$61.4M | −$67.7M | −$67.0M | −$69.5M | −$65.1M |
| Net income | −$26.6M | −$29.5M | −$34.1M | −$55.2M | −$62.3M | −$60.5M | −$63.5M | −$59.5M |
| EPS (diluted) | −$0.89 | −$0.95 | −$1.02 | −$1.58 | −$1.77 | −$1.64 | −$1.65 | −$1.54 |
| Balance sheet | ||||||||
| Cash and equivalents | $192.6M | $192.4M | $122.7M | $127.3M | $140.7M | $91.1M | $88.9M | $98.7M |
| Total assets | $495.1M | $496.8M | $709.3M | $665.1M | $630.5M | $806.9M | $750.2M | $735.1M |
| Total liabilities | $27.2M | $53.2M | $48.9M | $50.9M | $57.1M | $67.1M | $61.8M | $90.9M |
| Long-term debt | — | $28.3M | $28.5M | $28.7M | $28.9M | $29.2M | $29.4M | $59.3M |
| Shareholders' equity | $468.0M | $443.6M | $660.4M | $614.2M | $573.4M | $739.8M | $688.4M | $644.2M |
| Cash flow | ||||||||
| Operating cash flow | −$17.4M | −$27.6M | −$41.4M | −$47.9M | −$47.8M | −$43.3M | −$62.2M | −$44.2M |
| Capital expenditure | −$8.00K | $449.0K | $851.0K | $36.0K | $26.0K | $20.0K | $0 | $0 |
| Free cash flow | −$17.4M | −$28.0M | −$42.2M | −$48.0M | −$47.8M | −$43.3M | −$62.2M | −$44.2M |
From Disc Medicine Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Disc Medicine Inc
- Headquarters
- Watertown, Massachusetts From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International